EUVIMEDEUVIMED entdecken
Crossref

Heparin Management in Extracorporeal Circulation: Current Evidence and Clinical Perspectives

Eirini Chaidogianni, Polychronis Antonitsis, Despoina G Sarridou, Georgios Theodoros Karapanagiotidis

Aristotle University of Thessaloniki · 16.05.2026

DOI: 10.26262/abj.v8i2.11440 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Aristotle University of Thessaloniki, erschienen am 16.05.2026. Verfasst von Eirini Chaidogianni und 3 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Unfractionated heparin remains the most widely used anticoagulant factor during cardiac surgery due to its rapid onset of action, extensive clinical experience, convenience in titration, and reversibility with protamine sulfate. The widespread clinical use of heparin is attributed to its anticoagulant activity, achieved through potentiation of antithrombin III and subsequent inhibition of thrombin and activated factor Xa. Variability in heparin responsiveness may arise due to antithrombin deficiency, hemodilution, hypothermia, systemic inflammation, renal dysfunction, or previous heparin exposure, which complicate anticoagulation management. Thus, accurate perioperative anticoagulation management is considered essential in modern cardiac surgery. Activated Clotting Time (ACT) does not always provide the desired accuracy for determining the amount of heparin administered during extracorporeal circulation. Therefore, an individualized heparin management strategy is advocated to provide optimal anticoagulation. The Hepcon system is based on a dose-response curve, which customizes the required heparin dosage for each patient, as well as the required dose of protamine to reverse its action. Moreover, integration of viscoelastic trials (TEG/ROTEM) allow for a better understanding of the clot formation process and, thus, optimize heparin dosing, minimize bleeding risk, and reduce thrombotic complications. The major adverse reaction is heparin-induced thrombocytopenia (HIT), an immune response characterized by a significant decrease in platelet count and an increased risk of thrombosis. It mandates prompt diagnosis with immunoassays and functional assays, while alternative coagulation strategies could be implemented to prevent thrombotic complications. Overall, a comprehensive understanding of heparin pharmacology, monitoring strategies, complication management, and individualized hemostatic approaches is crucial for improving patient outcomes during any type of cardiac surgery.

Schlagwörter

unfractionated heparinextracorporeal circulationcardiac surgeryanticoagulation managementantithrombin IIIactivated clotting timeviscoelastic coagulation assaysTEGrotational thromboelastometryheparin-induced thrombocytopenia

Zitieren

APA

Chaidogianni, E., Antonitsis, P., Sarridou, D. G., & Karapanagiotidis, G. T. (2026). Heparin Management in Extracorporeal Circulation: Current Evidence and Clinical Perspectives. Aristotle University of Thessaloniki. https://doi.org/10.26262/abj.v8i2.11440

Vancouver

Chaidogianni E, Antonitsis P, Sarridou DG, Karapanagiotidis GT. Heparin Management in Extracorporeal Circulation: Current Evidence and Clinical Perspectives. Aristotle University of Thessaloniki. 2026. doi:10.26262/abj.v8i2.11440

BibTeX
@article{Chaidogianni2026,
  author = {Chaidogianni, Eirini and Antonitsis, Polychronis and Sarridou, Despoina G and Karapanagiotidis, Georgios Theodoros},
  title = {Heparin Management in Extracorporeal Circulation: Current Evidence and Clinical Perspectives},
  journal = {Aristotle University of Thessaloniki},
  year = {2026},
  doi = {10.26262/abj.v8i2.11440}
}
Kostenlos starten →